micro-community-banner
 
  • Saved

Evaluation of matrix metalloproteinase-9 plasma levels in untreated new Relapsing-remitting multiple sclerosis patients and their first-degree family

Evaluation of matrix metalloproteinase-9 plasma levels in untreated new Relapsing-remitting multiple sclerosis patients and their first-degree family

Source : https://link.springer.com/article/10.1007/s11011-021-00758-9

Matrix metalloproteinase, especially Matrix metalloproteinase-9 (MMP-9) has vital roles in the disruption of blood barrier, neuroinflammation and pathogenesis of multiple sclerosis (MS) patients. The goal of this study is to...

  • Saved

Concurrent axon and myelin destruction differentiates X‐linked adrenoleukodystrophy from multiple sclerosis

Concurrent axon and myelin destruction differentiates X‐linked adrenoleukodystrophy from multiple sclerosis

Source : https://onlinelibrary.wiley.com/doi/10.1002/glia.24042

Caroline G. Bergner , Jonas Franz , Franziska van der Meer , Christine Stadelmann , Corresponding Author Institute of Neuropathology, University Medical Center Göttingen, Göttingen, Germany Correspondence Christine Stadelmann, Institute...

  • Saved

Motor Cortical Activation Assessment in Progressive Multiple Sclerosis Patients Enrolled in Gait Rehabilitation: A Secondary Analysis of the RAGTIME Trial Assisted by Functional Near-Infrared Spectroscopy

Motor Cortical Activation Assessment in Progressive Multiple Sclerosis Patients Enrolled in Gait Rehabilitation: A Secondary Analysis of the RAGTIME Trial Assisted by Functional Near-Infrared Spectroscopy

Source : https://www.mdpi.com/2075-4418/11/6/1068

This study aimed to determine cortical activation responses to two different rehabilitative programs, as measured through functional near-infrared spectroscopy (fNIRS). As a secondary analysis of the RAGTIME trial, we studied...

  • Saved

Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients

Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients

Source : https://www.nature.com/articles/s41598-021-91912-x

Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription...

  • Saved